A qué la marca si es importante (VII): Pfizer de viaje a la India (Aurobindo)

Mas...

Mas...


Regresa Pfizer a esta sección ya repetitiva...

Aurobindo has sold rights to 39 generic solid oral dose products for the United States, 20 for Europe plus and 11 for France. These medicines cover a broad range of therapeutic areas, including cardiovascular disease and central nervous system disorders. Pfizer will commercialise these drugs through its Greenstone subsidiary.

As per Pfizer's data, the global generic market represents about $270 billion. Solid oral dose products are the largest drug category in the non-exclusive market. This category is anticipated to continue its rapid increase in market share and has an estimated growth potential of over $500 billion within the next five years.

The products expand Pfizer's growing generics portfolio and are versions of drugs originally made by other companies, Pfizer said in a press release.